- Bird Flu Virus in Canadian Teen Shows Mutations That Could Help It Spread Among Humans
- Flu, COVID Vaccination Rates Remain Low as Winter Nears
- ’10 Americas:’ Health Disparities Mean Life Expectancy Varies Across U.S.
- Short-Term Hormone Therapy for Menopause Won’t Harm Women’s Brains
- Could a Vitamin Be Effective Treatment for COPD?
- Woman Receives World’s First Robotic Double-Lung Transplant
- Flavored Vapes Behind Big Surge in U.S. E-Cigarette Sales
- Reading Beyond Headline Rare For Most on Social Media, Study Finds
- Meds Like Ozempic Are Causing Folks to Waste More Food
- Fibroids, Endometriosis Linked to Shorter Life Spans
Trulance Approved for Chronic Constipation
Trulance (plecanatide) has been approved by the U.S. Food and Drug Administration to treat persistent constipation of unknown (idiopathic) cause in adults.
Some 42 million people in the United States are affected by constipation, according to the National Institutes of Health. Once-daily Trulance is designed to stimulate the upper gastrointestinal tract to secrete fluid and “support regular bowel function,” the FDA said in a news release.
The oral drug was evaluated in two 12-week clinical studies involving a total of 1,775 adults with chronic constipation.
Diarrhea was the most common side effect. If diarrhea becomes severe, users should stop taking Trulance and contact a doctor, the FDA advised.
Trulance is produced by New York City-based Synergy Pharmaceuticals.
More information
Visit the FDA to learn more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.